topotecan has been researched along with Dysmyelopoietic Syndromes in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (24.00) | 18.2507 |
| 2000's | 18 (72.00) | 29.6817 |
| 2010's | 1 (4.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L | 1 |
| Bloomfield, CD; de Castro, C; Grinblatt, DL; Hars, V; Larson, RA; Nattam, S; Powell, BL; Silverman, LR; Stone, RM; Vardiman, JW; Yu, D | 1 |
| Albitar, M; Andreeff, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Thomas, D | 1 |
| Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA | 1 |
| Cripe, LD; Pennington, K; Stender, MJ; Stephens, A; Stoner, C; Vaena, DA; Walker, P; Yiannoutsos, CT; Young, C | 1 |
| Bolaños-Meade, J; Gojo, I; Guo, C; Karp, JE | 1 |
| Diehl, V; Hoffmann, M; Seiberlich, B; Staib, P; Tesch, H; Weihrauch, MR | 1 |
| Mufti, GJ | 1 |
| Grinblatt, DL; Hollis, D; Kastrissios, H; Klein, CE; Larson, RA; Miller, AA; Ratain, MJ; Rosner, GL; Yu, D | 1 |
| Billmeier, J; Galili, N; Gohar, S; Lisak, L; Mumtaz, M; Pervaiz, H; Raza, A; Wahid, K | 1 |
| Beran, M; Cortes, J; Estey, E; Giles, F; Kantarjian, H; Keating, M; O'Brien, S; Pierce, S; Plunkett, W; Shan, J | 1 |
| Jin, J; Liu, JQ; Qian, WB; Zhang, WF | 1 |
| Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
| Abbruzzese, JL; al-Bitar, M; Andreeff, M; Arbuck, S; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; Moore, M; O'Brien, S; Pierce, S | 1 |
| Cheson, BD | 1 |
| Beran, M; Kantarjian, H | 2 |
| Estey, EH | 1 |
| Eom, HS; Kim, CC; Kim, DW; Kim, HJ; Lee, JW; Min, CK; Min, WS; Park, SJ | 1 |
| Armour , WE; Huntington, MO; Krell, KE; Liljenquist, JE | 1 |
| Beran, M; Cortes, J; Despa, S; Estey, EH; Faderl, S; Giles, FJ; Kantarjian, H; Koller, CA; O'Brien, S; Shen, Y; Thomas, DA | 1 |
| Ariyanaygam, S; Atkins, L; DeAngelo, DJ; Fowler, DJ | 1 |
| Hahn, JS; Jang, JH; Ko, YW; Lee, ST; Min, YH; Suh, HC | 1 |
| List, AF | 1 |
4 review(s) available for topotecan and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Emerging therapeutic and supportive care approaches for the myelodisplastic syndromes.
Topics: DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Myelodysplastic Syndromes; Recombinant Proteins; Stem Cell Transplantation; Topotecan | 2004 |
Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes.
Topics: Anthracyclines; Antineoplastic Agents; Cytarabine; Dose-Response Relationship, Drug; Harringtonines; Homoharringtonine; Humans; Myelodysplastic Syndromes; Pyrimidines; Topotecan | 1998 |
Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Humans; Idarubicin; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Topotecan; Vidarabine | 1998 |
New approaches to the treatment of myelodysplasia.
Topics: Amifostine; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Prognosis; Proto-Oncogene Mas; Risk Factors; Severity of Illness Index; Thalidomide; Topotecan; Treatment Outcome | 2002 |
11 trial(s) available for topotecan and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan | 2009 |
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Endothelial Growth Factors; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Liposomes; Lymphokines; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Prognosis; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome | 2003 |
Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Drug Administration Schedule; Enzyme Inhibitors; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Topotecan; Treatment Outcome | 2004 |
A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Demography; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate; Topotecan; Treatment Outcome | 2004 |
Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cytarabine; Disease-Free Survival; Female; Hemoglobinometry; Humans; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Topotecan; Treatment Outcome | 2004 |
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Patient Compliance; Topotecan | 2006 |
Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Thalidomide; Time Factors; Topotecan; Treatment Outcome | 2006 |
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Diarrhea; Female; Fever; Follow-Up Studies; Genes, ras; Humans; Leukemia, Myelomonocytic, Chronic; Life Tables; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Remission Induction; Stomatitis; Survival Analysis; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1996 |
Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Platelet Count; Remission Induction; Risk Assessment; Survival Rate; Thrombocytopenia; Topotecan | 1999 |
10 other study(ies) available for topotecan and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Humans; Idarubicin; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Analysis; Topotecan; Vidarabine | 2006 |
[Inhibition effect of topotecan on human myelodysplastic syndrome cells in vitro and in vivo].
Topics: Animals; Antineoplastic Agents; Apoptosis; DNA Topoisomerases, Type I; Down-Regulation; Humans; Mice; Mice, SCID; Myelodysplastic Syndromes; Neoplasm Transplantation; Topotecan; Tumor Cells, Cultured | 2006 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |
Hycamtin achieves promising results in study of patients with leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Ovarian Neoplasms; Remission Induction; Topotecan | 1996 |
Topotecan in the treatment of hematologic malignancies.
Topics: Aged; Antineoplastic Agents; Enzyme Inhibitors; Humans; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome | 1998 |
Topotecan-based combination chemotherapy in patients with transformed chronic myelogenous leukemia and advanced myelodysplastic syndrome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan | 2000 |
Temporary reversal by topotecan of marked insulin resistance in a patient with myelodysplastic syndrome: case report and possible mechanism for tumor necrosis factor alpha (TNF-alpha)-induced insulin resistance.
Topics: Aged; Enzyme Inhibitors; Humans; Insulin Resistance; Male; Myelodysplastic Syndromes; Time Factors; Topotecan; Tumor Necrosis Factor-alpha | 2001 |
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Karyotyping; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Survival Analysis; Topotecan; Vidarabine | 2001 |
A new case of isolated del(12)(q15q22) in myelodysplastic syndrome.
Topics: Aged; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 12; Combined Modality Therapy; Humans; Male; Myelodysplastic Syndromes; Topotecan | 2001 |
Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Salvage Therapy; Survival Rate; Topotecan; Treatment Outcome | 2001 |